We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

F.D.A. Panel Rejects Drug for Obesity

Law360 (June 14, 2007, 12:00 AM EDT) -- The French drug company Sanofi-aventis announced on Wednesday that a Food and Drug Administration advisory panel has voted unanimously not to recommend approving its new weight loss drug, citing concerns about its effectiveness and safety.

The drug, known as rimonabant and already sold in 37 countries under the brand name Acomplia, was approved by the European Medical Agency in June 2006. Sanofi had intended to market it in the United States as Zimulti.

The drug is indicated for treating obesity, but has not been shown to...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.